Two primary and three MYC-amplified cell lines localized at the cerebellum and disseminated at leptomeninges have been treated with Hu5F9-G4 antibody (also named Magrolimab) intraperitoneally, and a reduction of tumor burden and increase of OS in mice have been detected. This evidence concerns the gene MYC and neoplasm.